|
|
|
|
HyzaarForbes Rita, research analyst Kevin McCarthy said he remains cautious on DuPont due to the company's patent expirations for hypertension drugs Cozaar and Hyzaar and a ... DuPont "neutral," target price reduced Jan 13, 2006 New Ratings DuPont’s Cozaar/Hyzaar pharma patents are scheduled to expire in 2010, the analyst says. The EPS estimate for 2006 has been reduced from $2.75 to $2.30. Merck Unveils Plan to Reclaim Leadership Position Dec 15, 2005 Business Wire (press release), 2005 SALES ----- ZOCOR (Cholesterol modifying) $4.2 to $4.5 billion FOSAMAX (Osteoporosis) $3.1 to $3.4 billion COZAAR/HYZAAR (Hypertension) $2.9 ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |